NEW YORK (GenomeWeb) – Veracyte late on Wednesday priced its previously announced public offering of 5 million shares of its common stock at $10.25 per share to raise an anticipated $51.3 million in gross proceeds.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.